SEATTLE and
CAMBRIDGE, England, Nov. 2, 2021
/PRNewswire/ -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or
"Nautilus"), a company pioneering a single-molecule protein
analysis platform for quantifying the proteome, and
Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life
sciences research tools, today announced a strategic development
and supply partnership.
The relationship leverages Abcam's industry-leading recombinant
monoclonal antibody development technologies and expertise to
enhance Nautilus' reagent research and development, and establishes
a long-term supply relationship between the companies. The
partnership will initially focus on the collaborative development
of affinity binding reagents for use on the Nautilus proteomic
analysis system, and will expand in the near future to the
large-scale manufacture and supply of reagents for
commercialization.
"We are excited to be working closely with Abcam to build
reagents that we believe will further enhance our proteomic
analysis methods," said Sujal Patel,
co-founder and CEO of Nautilus Biotechnology. "They, like us,
envision a future in which proteomic data is expected to become an
increasingly important resource that has the potential to support
the creation of more effective drugs and diagnostics. Our ability
to partner with a company as respected and successful as Abcam
provides a strong vote of confidence in that future, and in the
promise of the Nautilus protein analysis platform to help make it a
reality."
Abcam's scale and recombinant antibody manufacturing expertise
is expected to support Nautilus in meeting its long-term reagent
supply needs from research and development through to
commercialization.
"The prospect of biomedical researchers being able to
interrogate the proteome at a more comprehensive level offers
exciting possibilities for discovery and innovation across multiple
disease areas," said Alan Hirzel,
CEO of Abcam. "By combining Nautilus' protein analysis platform and
Abcam's antibody discovery, development and manufacturing
expertise, we hope to better support scientists in the development
of drugs and diagnostic tools that ultimately improve outcomes for
patients."
Under the terms of the agreement, Abcam will provide Nautilus
with antibodies that are expected to add to and enhance its own
library of affinity binding reagents, highlighting the open and
customizable nature of Nautilus' technology. With simple labeling
chemistry, the Nautilus platform is designed for use with virtually
any biological reagent.
About Nautilus Biotechnology, Inc.
Based in Seattle, Washington,
Nautilus (Nasdaq: NAUT) is a development stage life sciences
company creating a platform technology for quantifying and
unlocking the complexity of the proteome. Nautilus' mission is to
transform the field of proteomics by democratizing access to the
proteome and enabling fundamental advancements across human health
and medicine. To learn more about Nautilus, visit
www.nautilus.bio
About Abcam plc
As a global life sciences company, Abcam identifies, develops,
and distributes high-quality biological reagents and tools that are
crucial to research, drug discovery and diagnostics. Working across
the industry, the Company supports life scientists to achieve their
mission, faster.
Abcam partners with life sciences organizations to co-create
novel binders for use in drug discovery, in vitro
diagnostics and therapeutics, driven by the Company's proprietary
discovery platforms and world-leading antibody expertise.
By constantly innovating its binders and assays, Abcam is
helping advance the global understanding of biology and causes of
disease, which enables new treatments and improved health. The
Company's pioneering data-sharing approach gives scientists
increased confidence in their results by providing validation, user
comments and peer-reviewed citations for its 90,000 products.
With 14 sites globally, many of Abcam's over 1,600-strong team
are located in the world's leading life sciences research hubs,
complementing a global network of service and support.
To find out more, please
visit www.abcam.com and corporate.abcam.com.
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of federal securities laws. You can identify
forward-looking statements by words such as "may," "will," "could,"
"can," "would," "should," "expect," "intend," "plan," "anticipate,"
"believe," "estimate," "predict," "project," "potential," "poised,"
"continue," "ongoing" or the negative of these terms or other
comparable terminology, but not all forward-looking statements will
contain these words. Forward-looking statements in this press
release include, but are not limited to, statements regarding the
potential functionality and performance of Nautilus' product
platform, its potential impact on pharmaceutical development and
drug discovery, and market opportunities available to Nautilus or
Abcam generally. These statements are based on numerous assumptions
concerning the collaboration between Abcam and Nautilus including
but not limited to expectations as to the success of that
collaboration, expectations regarding the ability of that
collaboration to enhance and/or accelerate Nautilus' development
efforts and to enable Nautilus to meet long term reagent supply
needs, and expectations regarding the development of Nautilus'
products and target markets, generally, and involve substantial
risks, uncertainties and other factors that may cause actual
results, levels of activity, performance or achievement to be
materially different from the information expressed or implied by
these forward-looking statements. We cannot assure you that the
forward-looking statements in this press release or the assumptions
upon which they are based will prove to be accurate. Risks and
uncertainties that could materially affect the accuracy and outcome
of Nautilus' and Abcam's assumptions and its ability to achieve the
forward-looking statements set forth in this press release include
(without limitation) the following: Nautilus' product platform is
not yet commercially available and remains subject to significant
scientific and technical development, which is inherently
challenging and difficult to predict, particularly with respect to
highly novel and complex products such as those being developed by
Nautilus. Even if Nautilus' development efforts are successful, the
product platform will require substantial validation of its
functionality and utility in life science research. In the course
of Nautilus' scientific and technical development and associated
product validation and commercialization, Nautilus or Abcam may
experience material delays as a result of unanticipated
events. For a more detailed description of additional risks
and uncertainties facing Nautilus and its development efforts,
investors should refer to the Registration Statement on Form S-4
and related documents filed with the SEC. For a more detailed
description of additional risks and uncertainties facing Abcam and
its development and business strategy see the important factors
discussed under the caption "Risk Factors" in Abcam's prospectus
pursuant to Rule 424(b) filed with the U.S. Securities and Exchange
Commission ("SEC") on 22 October
2020, which is on file with the SEC and is available on the
SEC website at www.sec.gov, as such factors may be updated from
time to time in Abcam's other filings with the SEC. The
forward-looking statements in this press release are as of the date
of this press release. Except as otherwise required by applicable
law, Nautilus and Abcam disclaim any duty to update any
forward-looking statements. You should, therefore, not rely on
these forward-looking statements as representing our views as of
any date subsequent to the date of this press release.
Logo -
https://mma.prnewswire.com/media/1675313/Nautilus_Abcam_logo.jpg